154 related articles for article (PubMed ID: 24983019)
41. Harm reduction--from a conceptual framework to practical experience: the example of Germany.
Michels II; Stöver H
Subst Use Misuse; 2012; 47(8-9):910-22. PubMed ID: 22676562
[TBL] [Abstract][Full Text] [Related]
42. Public Health Approaches Toward Eliminating Hepatitis C Virus in Rhode Island.
Murphy M; Howe K; Marak T; Bertrand T; Maynard M; Ndoye CD; Joseph R; Fingerut J; Chan PA
R I Med J (2013); 2020 Jun; 103(5):22-25. PubMed ID: 32481775
[TBL] [Abstract][Full Text] [Related]
43. Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago.
Boodram B; Golub ET; Ouellet LJ
Drug Alcohol Depend; 2010 Sep; 111(1-2):136-45. PubMed ID: 20472373
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of hepatitis C virus infection among clients of HIV counseling and testing sites--Connecticut, 1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Jul; 50(27):577-81. PubMed ID: 11475165
[TBL] [Abstract][Full Text] [Related]
45. Utilization of preventive health services by HIV-seronegative injection drug users.
McGarry KA; Stein MD; Clarke JG; Friedmann PD
J Addict Dis; 2002; 21(2):93-102. PubMed ID: 11916375
[TBL] [Abstract][Full Text] [Related]
46. Demystifying the injection drug user: willingness to participate in traditional drug treatment services among participants in a needle exchange program.
MacMaster SA; Vail KA
J Psychoactive Drugs; 2002; 34(3):289-94. PubMed ID: 12422939
[TBL] [Abstract][Full Text] [Related]
47. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?
de Vos AS; van der Helm JJ; Matser A; Prins M; Kretzschmar ME
Addiction; 2013 Jun; 108(6):1070-81. PubMed ID: 23347124
[TBL] [Abstract][Full Text] [Related]
48. Physicians should support needle exchange in Rhode Island.
Lewis DC; Rich JD
Med Health R I; 1996 Jun; 79(6):206. PubMed ID: 8797314
[No Abstract] [Full Text] [Related]
49. [Epidemiology of hepatitis C and human immunodeficiency virus infections among injecting drug users in Hungary--what's next?].
Gyarmathy VA; Rácz J
Orv Hetil; 2010 Mar; 151(10):365-71. PubMed ID: 20178967
[TBL] [Abstract][Full Text] [Related]
50. Comprehensive medical care among HIV-positive incarcerated women: the Rhode Island experience.
Farley JL; Mitty JA; Lally MA; Burzynski JN; Tashima K; Rich JD; Cu-Uvin S; Spaulding A; Normandie L; Snead M; Flanigan TP
J Womens Health Gend Based Med; 2000; 9(1):51-6. PubMed ID: 10718506
[TBL] [Abstract][Full Text] [Related]
51. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.
Kemp R; Miller J; Lungley S; Baker M
N Z Med J; 1998 Feb; 111(1060):50-3. PubMed ID: 9539916
[TBL] [Abstract][Full Text] [Related]
52. [The efficacy of needle exchange programs in the prevention of HIV and hepatitis infection among injecting drug users].
Takács IG; Demetrovics Z
Psychiatr Hung; 2009; 24(4):264-81. PubMed ID: 19949245
[TBL] [Abstract][Full Text] [Related]
53. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
54. [Risk factors for hepatitis C among injecting drug users in Oslo].
Dalgard O; Egeland A; Ervik R; Vilimas K; Skaug K; Steen TW
Tidsskr Nor Laegeforen; 2009 Jan; 129(2):101-4. PubMed ID: 19151801
[TBL] [Abstract][Full Text] [Related]
55. How to run a successful needle exchange program.
AIDS Alert; 1997 Nov; 12(11):129-31. PubMed ID: 11364772
[TBL] [Abstract][Full Text] [Related]
56. Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system.
Mojtahedzadeh V; Razani N; Malekinejad M; Vazirian M; Shoaee S; Saberi Zafarghandi MB; Hernandez AL; Mandel JS
AIDS Behav; 2008 Jul; 12(4 Suppl):S7-12. PubMed ID: 18521737
[TBL] [Abstract][Full Text] [Related]
57. Reducing the risk of HIV infection associated with illicit drug use.
American Academy of Pediatrics Committee on Pediatric AIDS
Pediatrics; 2006 Feb; 117(2):566-71. PubMed ID: 16452382
[TBL] [Abstract][Full Text] [Related]
58. Social context of needle selling in Baltimore, Maryland.
Latkin CA; Davey MA; Hua W
Subst Use Misuse; 2006; 41(6-7):901-13. PubMed ID: 16809178
[TBL] [Abstract][Full Text] [Related]
59. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
[TBL] [Abstract][Full Text] [Related]
60. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites.
Smith BD; Teshale E; Jewett A; Weinbaum CM; Neaigus A; Hagan H; Jenness SM; Melville SK; Burt R; Thiede H; Al-Tayyib A; Pannala PR; Miles IW; Oster AM; Smith A; Finlayson T; Bowles KE; Dinenno EA
Clin Infect Dis; 2011 Oct; 53(8):780-6. PubMed ID: 21921221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
